(NewsDirect)
Dr Jennifer Connelly, MD, the PrincipalInvestigator (PI) of the IQ-AI Limited sponsored phase one clinicaltrial that is being conducted at the Medical College of Wisconsin,joined Proactive's Stephen Gunnion with a positive update from itstreatment for recurring glioblastoma patients.
Connelly explained that glioblastoma, themost common malignant brain tumour, significantly impacts brainfunction, highlighting the importance of clinical trials to improvepatient quality of life.
The trial,opened nearly two years ago, investigates gallium maltolate, an oralmedication showing promise in preclinical studies and animal modelsfor efficacy against tumour cells. This phase focuses on drugtolerance, with patients reporting ease of use compared to traditionaltreatments and the ability to maintain normal daily activities.
An expanded access programme (EAP), alsoknown as compassionate use, has been launched by IA-AI subsidiaryImaging Biometric to allow wider access to gallium maltolate acrossthe country, benefiting patients unable to travel to the MedicalCollege of Wisconsin. The EAP, approved by the FDA, aims to collectadditional safety and toxicity data, contributing to the trial'sfindings and supporting the progression towards a phase two clinicaltrial.
The next milestone, by the end of 2024, involvesconcluding the phase one trial, determining the maximum tolerateddose, and preparing for the phase two trial slated for 2025, focusingon safety and beginning to evaluate efficacy.
ContactDetails
Proactive UK
Proactive UK
+44 207989 0813
UKEditorial@proactiveinvestors.com
Copyright (c) 2024 TheNewswire - All rights reserved.